Woodward Diversified Capital LLC Acquires 1,417 Shares of Abbott Laboratories $ABT

Woodward Diversified Capital LLC raised its position in shares of Abbott Laboratories (NYSE:ABT) by 30.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 6,056 shares of the healthcare product maker’s stock after acquiring an additional 1,417 shares during the period. Woodward Diversified Capital LLC’s holdings in Abbott Laboratories were worth $824,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Hughes Financial Services LLC purchased a new stake in Abbott Laboratories during the 1st quarter valued at about $27,000. Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the first quarter valued at approximately $28,000. Elequin Capital LP purchased a new stake in shares of Abbott Laboratories during the first quarter valued at approximately $30,000. JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories during the 1st quarter valued at $32,000. Finally, Vision Financial Markets LLC purchased a new stake in Abbott Laboratories during the 1st quarter valued at $33,000. 75.18% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Trading Down 0.3%

Shares of Abbott Laboratories stock opened at $133.53 on Thursday. The company has a market capitalization of $232.39 billion, a P/E ratio of 16.73, a P/E/G ratio of 2.54 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company has a fifty day moving average of $131.63 and a 200 day moving average of $131.24. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Raymond James Financial dropped their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research report on Friday, July 18th. Mizuho raised their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, July 16th. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Wells Fargo & Company cut their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Finally, BTIG Research cut their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $145.39.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.